IGF::OT::IGF STATIN THERAPY TO REDUCE DISEASE PROGRESSION FROM LIVER CIRRHOSIS TO CANCER

该研究是一项他汀类药物的IIb期、双盲、安慰剂对照试验，旨在评估他汀类药物治疗对80例终末期肝病(MELD)≤20且无肝细胞癌（HCC）证据的肝硬化患者疾病进展的影响。参与者将从雪松西奈医学中心（CSMC）和西北大学（NWU）的肝脏病学诊所招募，并将包括目前正在等待或正在评估的肝移植患者。

The proposed study is a Phase IIb, double-blinded, placebo-controlled trial of a statin to evaluate the impact of statin treatment on disease progression in 80 patients with liver cirrhosis who have a current Model for End-Stage Liver Disease (MELD) ≤ 20 and no evidence of Hepatocellular carcinoma (HCC). Participants shall be recruited from hepatology clinics at Cedar Sinai Medical Center (CSMC) and Northwestern University (NWU) and shall include patients who are currently waitlisted, or under evaluation, for a liver transplant.